Big five’s earnings fall 11% on government’s forced price cut for drugs

Published: 2013-02-14 07:00:00

Updated: 2013-02-14 07:00:00

Korea’s five major drug companies saw their combined earnings drop 11 percent in 2012 from a year earlier, an online pharmaceutical information provider said yesterday, pointing to their troubles stemming from the government’s push to slash drug prices and its sweeping crackdown on unfair trade p...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK